Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Zura Bio Ltd ZURA

Healthcare Biotechnology
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase... see more

Current News (NDAQ:ZURA)

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Business Wire November 13, 2025

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Business Wire August 20, 2025

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Business Wire August 14, 2025

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 17, 2025

Zura Bio Announces Chief Financial Officer Transition

Business Wire July 1, 2025

Zura Bio to Present at the Jefferies Global Healthcare Conference

Business Wire May 27, 2025

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

Business Wire May 20, 2025

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Business Wire May 8, 2025

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Business Wire March 25, 2025
View More News ››

Opinion & Analysis (NDAQ:ZURA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZURA)

ZURA ...... You're rich !!!!!!

Ka f'king booom
Iseneschal - March 22, 2023
View more Bullboard ››

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral properties in Canada. It ...
View More »